Latest Breaking News On - Pharma limited nasdaq - Page 1 : comparemela.com
OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”), today announced the pricing of a Company best efforts registered direct offering of 2,666,667 ordinary shares at an offering price of $1.50 .
LondonCity-ofUnited-kingdomExchange-commissionPharma-limited-nasdaq